公开(公告)号：US20170240586A1

公开(公告)日：2017-08-24

申请号：US15439303

申请日：2017-02-22

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yat Sun Or ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He

IPC: C07J43/00 ,  C07J9/00

CPC classification number: C07J43/003 ,  C07J9/00 ,  C07J9/005 ,  C07J21/00 ,  C07J31/006 ,  C07J41/0061 ,  C07J41/0094 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

公开(公告)号：US09718851B2

公开(公告)日：2017-08-01

申请号：US14933752

申请日：2015-11-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jay R. Luly ,  Bin Wang ,  Guoqiang Wang ,  Yat Sun Or

IPC: A01N43/04 ,  A61K31/70 ,  C07H19/10 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/06 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068

CPC classification number: C07H19/10 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/06

Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R4, R5a, R5b, Rb5, Rb6 and D are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.

公开(公告)号：US20160229886A1

公开(公告)日：2016-08-11

申请号：US15041811

申请日：2016-02-11

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Ruichao Shen ,  Yat Sun Or ,  Guoqiang Wang

IPC: C07J41/00 ,  C07J43/00

CPC classification number: C07J41/0061 ,  C07J9/005 ,  C07J43/003

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.

Abstract translation: 本发明提供式I化合物：包含这些化合物的药物组合物和使用这些化合物治疗或预防由FXR和/或TGR5介导的疾病或病症的方法。

公开(公告)号：US20160185815A1

公开(公告)日：2016-06-30

申请号：US14951989

申请日：2015-11-25

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Jiang Long ,  Peng Dai ,  Xuechao Xing ,  Jing He

IPC: C07J41/00 ,  C07J43/00

CPC classification number: C07J41/0066 ,  C07J9/005 ,  C07J41/0055 ,  C07J41/0088 ,  C07J41/0094 ,  C07J43/003 ,  C07J43/006 ,  C07J51/00

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

Abstract translation: 本发明提供式I化合物，包含这些化合物的药物组合物和使用这些化合物预防或治疗FXR介导的或TGR5介导的疾病或病症的方法。

公开(公告)号：US20160130304A1

公开(公告)日：2016-05-12

申请号：US14931384

申请日：2015-11-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  In Jong Kim ,  Yat Sun Or

IPC: C07K7/52 ,  A61K45/06 ,  A61K38/13

CPC classification number: A61K45/06 ,  A61K31/7056 ,  A61K38/13 ,  A61K38/21 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

Abstract: The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US09221878B2

公开(公告)日：2015-12-29

申请号：US14469403

申请日：2014-08-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  In Jong Kim

IPC: C07K7/64 ,  A61K38/13 ,  A61K45/06 ,  A61K38/21 ,  A61K38/00

CPC classification number: A61K38/13 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  C07K7/645 ,  Y02A50/463 ,  A61K2300/00

Abstract: The present invention relates to novel cyclosporine analogs having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analog compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及具有抗HCV的抗病毒活性的新型环孢菌素类似物，可用于治疗HCV感染。 更具体地说，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US08927739B2

公开(公告)日：2015-01-06

申请号：US14082406

申请日：2013-11-18

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  In Jong Kim ,  Hui Cao ,  Datong Tang ,  Yat Sun Or ,  Guoqiang Wang ,  Guoyou Xu

IPC: C07D209/54

CPC classification number: C07D209/54

Abstract: The present invention relates generally to an improved process for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of hepatits C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (Ia), (Ib) and (Ic):

Abstract translation: 本发明一般涉及一种制备5-氮杂螺[2.4]庚烷-6-羧酸及其衍生物的改进方法，其在合成生物活性分子中是有用的中间体，特别是在合成肝素C病毒NS5A抑制剂 。 特别地，本发明涉及制备式（Ia），（Ib）和（Ic）化合物的方法和中间体：

公开(公告)号：US08846638B2

公开(公告)日：2014-09-30

申请号：US13897023

申请日：2013-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Guoqiang Wang

IPC: C07H19/00 ,  A61K31/70 ,  C07H19/14 ,  C07H19/23 ,  A61K45/06 ,  A61K31/7076 ,  C07H19/10 ,  C07H19/20 ,  C07H19/207 ,  A61K31/7064

CPC classification number: C07H19/207 ,  A61K31/7064 ,  A61K31/7076 ,  A61K45/06 ,  C07H19/10 ,  C07H19/14 ,  C07H19/20 ,  C07H19/23 ,  A61K2300/00

Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.

Abstract translation: 本发明提供式I的核苷氨基磷酸酯化合物，其中R1，R2a，R2b，R3，R4，R5a，R5b，R6，R7，R8a，R8b，M和W如本文所定义。 本发明还包括含有式I化合物的药物组合物，这些化合物用于治疗病毒感染的方法，以及制备这些化合物的方法。

公开(公告)号：US20140287992A1

公开(公告)日：2014-09-25

申请号：US14299095

申请日：2014-06-09

Applicant: Enanta Pharmaceuticals, Inc. ,  AbbVie, Inc.

Inventor： Hui-Ju Chen ,  Keith F. McDaniel ,  Brian E. Green ,  Jason P. Shanley ,  Albert W. Kruger ,  Jorge Gandarilla ,  Dennie S. Welch ,  Russell D. Cink ,  Steven C. Cullen ,  Yonghua Gai ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07K5/083

CPC classification number: C07K5/081 ,  C07D487/04

Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

Abstract translation: 本发明涉及新的大环化合物和在需要用所述大环化合物进行这种治疗的受试者中治疗丙型肝炎感染的方法。 本发明还涉及包含本发明化合物或其药学上可接受的盐，酯或前药与药学上可接受的载体或赋形剂组合的药物组合物。

公开(公告)号：US20130165641A1

公开(公告)日：2013-06-27

申请号：US13684927

申请日：2012-11-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： In Jong Kim ,  Tongzhu Liu ,  Jiang Long ,  Guoqiang Wang ,  Yao-Ling Qiu ,  Heejin Kim ,  Yanchun Wang ,  Ly Tam Phan ,  Yat Sun Or

IPC: C07H17/08

CPC classification number: C07D493/08 ,  C07F9/65586 ,  C07H17/08

Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.